In conclusion, these studies have demonstrated or suggested that interfering with NRF2-driven NADPH generation can potentially impair tumor growth and survival affecting both anabolic processes and redox homeostasis, representing a promising therapeutic option against a number of different cancers. This evidence concerns the gene NFE2L2 and cancer.